ROANOKE, Va.--(BUSINESS WIRE)--Jan. 31, 2006--OcuCure Therapeutics is pleased to announce an investment by the Carilion Biomedical Institute (CBI), an organization that makes early stage investments in breakthrough technology. Terms of the investment are undisclosed. Roanoke based OcuCure is developing new proprietary drugs and technologies to reduce and prevent vision loss caused by eye diseases. OcuCure’s compounds have a novel mechanism of action and will introduce a new wave of differentiated drugs for the treatment of age-related macular degeneration (AMD). Research results have been very encouraging, and additional animal studies will be conducted at T.R. Lee Center for Ocular Pharmacology at Eastern Virginia Medical School.
